Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

Radient Restructured By A Planned Reverse Merger

July 25, 2015

living you said..ahooololoooololooooooooo

living said charter was ceo of Radient..please show where charter became CEO of AMDL Diagnostics Inc.? Unless you pay a few bucks to Delaware,you can not argue the fact that he is involved with AMDL Diagnostics Inc..We did pay the monies...Charter is not the CEO of AMDL Diagnostics Inc...Capiche? lol

"aussie 1, dennis charter:

named the CEO

"aussie 2 darren brown:

on the BOD (see 8k)
registered amdl-diagnostics.com (see who-is)"

Explain your logic that the aussies stole the name AMDL Diagnostics.com web site....lol That's right the aussies never registered AMDL Diagnostics.com, they registered AMDL-Diagnostics.com and cstamdl.com..Nice try..ahooololooololooooooooooooo

You might want to look at thjois post instead you understand...

As a little reminder
by dcspka • 3 hours ago

UniPharma has great expectations for DR-70/Onko-Sure.

"Since 2013, Uni Pharma successfully in-licensed DR-70®ELISA Test from USA and co-developed with Pharmigene. With great effort from Uni Pharma and Pharmigene, Taiwan-made DR-70®test passed TFDA and SGS audit and proudly received GMP and ISO 13485 certificate in March 2014. Furthermore, DR-70®receives Taiwan FDA marketing approval in August 2014 and CE certificate in September 2014.

DR-70®( licensed by Uni Pharma is approved by US FDA for colorectal cancer monitoring in 2008 and it is the only tumor marker approved for colorectal cancer monitoring by FDA since 1985. Serial testing using the DR-70®(by measure the concentration of Fibrin/fibrinogen degradation products, FDP) is to use as an aid in monitoring disease progression and treatment evaluation. Through its high accuracy, DR-70® has helped numerous clinical physicians and their patients worldwide.

Uni Pharma has noticed the medical advancement for cancer monitoring and therapies in Asia. The economic growth and increasing ratio of health related consumptions to GDP also encourages Uni Pharma takes its distributionship of DR-70® (in Taiwan to the next level and establishes a manufacturing site for Asia region. This allows Unipharma to ensure the supply chain and cold chain quality of DR-70® test to cover Asia-Pacific countries. Up to date, Uni Pharma has already exported DR-70® to India and Turkey. Other countries like Korea, China are under regulatory filing and expect to receive approval by Q4 2015 and 2017, respectively."

Notice the trademark DR-70® which Radient/AMDL owns. Notice the last and latest mention of Unipharma/DR-70 expansion to Turkey which was recently announced. Notice "Other countries like Korea, China are under regulatory filing and expect to receive approval by Q4 2015 and 2017, respectively."

UniPharma wants to Go Public on an American Exchange. Look for a Creative Partners with Provista/Radient.



July 23, 2015

Jim and Dc..Did we say "Smoke Screen or Cancer Screen" lol....The Aussie site is a preview to the new Radient Reverse Mergers..We like to call it "Insighter Information" you understand...It is funny how some here are trying to figure it All out and have no clue..Here is how you use the Davinci code...

"Trials have been conducted in America, Australia, Canada, China, Chile, Germany, Hong Kong, India, Korea,
Malaysia, Singapore, Taiwan, Turkey, and Vietnam that clinically proved the efficacy of the CST test to detect multiple cancers."

http://www.cstamdl.com/

"Our long term strategy and consideration for profit has given us a self-pay focus in Taiwan. However, we will respond to partner demand in countries like Turkey, Australia, and China when we bring Onko-Sure to those markets."

http://pharmaboardroom.com/interviews/interview-terry-lin-general-manager-and-freia-wei-senior-consultant-uni-pharma/

Conclusion...Uni-Pharma partners..

Turkey...Onko Result Subsidiary

Australia/New Zealand...Cancer Screen technologies

USA...AMDL Diagnostics Inc./Radient Pharmaceuticals a/k/a Provista Diagnostics/GCDX

China...Jade ? The only unknown at the time...

Sound confusing? Only to the confused you understand...



July 20, 2015

Two posts that Uni and GCDX by CetGoldseekerOK are not TRUE..Uni-Pharma only has exclusivity in Taiwan and not the other territories presented to Uni-Pharma..Here is the agreement.

This License Agreement (the “Agreement”), which shall be effective as of June 6, 2013, is by and between Uni Pharma Co., Ltd., a Taipei, Taiwan limited liability company (“UNI”) and Radient Pharmaceuticals Corporation (including its subsidiary AMDL Diagnostics Inc.) a Delaware incorporated United States company (“RXPC”).

Whereas, UNI wishes to hold a non-exclusive 5 year license (excepting Taiwan which remains exclusive per UNI-RXPC exclusive distribution agreement) to RXPC’s Onko-Sure and DR-70 cancer blood test kits (the “Tests”),

http://www.sec.gov/Archives/edgar/data/838879/000121390013003078/f8k061113ex10i_radientpharm.htm

The offices of CST is in La by AMDL Diagnostics Inc...This is great news, that we were already aware of you understand..What took the others to find it? lol

The Tustin office never closed...The person who claimed that, was not telling the truth you understand..lol

Cancer Screen Technologies Ltd

Registered Office:

7/F, China Overseas Building, 139 Hennessy Road, Wanchai, Hong Kong

Offices and Laboratory:

AMDL Diagnostics Inc.

2492 Walnut Ave, Suite 100, Tustin CA, 92780 USA



http://www.cstamdl.com/?page_id=81

http://www.cstamdl.com/

______________________________________________________________


july 15,2015


Jim..this is the change from Metropolis to Ingenuity...this development is great for Onko-Sure and RXPC shareholders.Notice one of the labs that LIKED Onko-Sure Cancer test.

"The dealmaking in Metropolis coincides with IPO plans of other players in the space, notably Dr Lal Pathlabs, SRL and Thyrocare, all of whom could list in 2015."

http://articles.economictimes.indiatimes.com/2015-01-02/news/57611417_1_warburg-pincus-metropolis-healthcare-pe-majors

https://www.facebook.com/OnkoSureIngenuityHealthcareIndia

8**********************************************************************************************************

Great Find Jim. This is why metropolis dropped the "Cancer 8*" from their website.Ingenuity is Metro and a collaboration of Metropolis and Arima

https://www.facebook.com/OnkoSureIngenuityHealthcareIndia

Onko Sure - A Product By Ingenuity Healthcare India, Mumbai, Maharashtra, India. 43 likes. Onko Sure™, A simple blood test to detect Cancer at early

http://www.metropolisindia.com/labs-home

Mumbai
Contact No: [phone]/ 33993939
SMS: Type MHL HV MUM <Name of Customer> and SMS to 56363
E-mail: [e-mail]
- See more at: http://www.metropolisindia.com/labs-home#sthash.apq5uJOB.dpuf

http://www.metropolisindia.com/index.php/our-team/management-team

About Onko Sure - A Product By Ingenuity Healthcare India

Page Info

Page Info

Start Date
Founded in 2014
Address
Mumbai, Maharashtra, India 400002


https://www.facebook.com/OnkoSureIngenuityHealthcareIndia/info?tab=page_info

****************************************************************************************

Radient Restructured By A Planned Reverse Merger

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115395738

july 15,2015

Jim You said Arima owns the shares of RXPC. GetGoldSeekerOK claims that retailers own RXPC shares. The wolfpack claims that Provista angel investors own around 59 percent of RXPC shares and 31 percent owned by the RXPC lenders, resulting in only 500,000 dollars of Radient debt which is the remaining accounts payable before Radient went into temporary hibernation. The monies from Uni-Pharma is paying off that debt.

Uni-Pharma is not the developer of the next generation Onko-Sure..DR-70 next generation is being developed by Provista Diagnostics and Global Cancer Diagnostics.Jim you stated that the GCDX agreement fell through..My insighter connections sys otherwise you understand.

In 2010, thanks to Freia’s help, we added a cancer-detection device—an in-vitro diagnostics (IVD) product—to our portfolio. The device is extremely efficacious in monitoring the progress of colorectal cancer treatment.

"Our vision is to take this product to different countries. We think Onko-Sure can benefit patients throughout the entire world. We own the license to manufacture it in Taiwan, and to sell it in a number of global markets, mostly in Asia Pacific and the Middle East. Penetrating these markets—our first international foray with a product we manufacture ourselves—will be a huge step for us."

"After we take that first step, we will look to develop an even better product."

JIM..the 5 year agreement between provista and radient to develop and commercialize the next generation DR-70/ONKO-sure ends in NOvember 2015.

"Freia Wei (FW): Based on our work with this product so far, we further gained the right to manufacture it in Taiwan. We are looking to transform our company from a pure distribution player to an organization that has the capability to make and develop its own products."

"To this end, we have recently established a manufacturing and distribution partnership with the company Pharmigene."

"As Freia began to mention, we are now looking to differentiate our business and move beyond distribution. To do so, we plan to increase our capital, and significantly expand our organization, over the next two years.

We are not a development company. Rather, our strength is in market research, sales, and promotion. We can connect to clinical demand: this is our strength. When we identify a product based on that demand, we can develop a very strong go-to-market strategy.

We need a partner to help us manufacture the product, which is why we have formed an alliance with Pharmigene. This way, we will not need our own factory for production purposes."

dcspka..the markets uni has focused on is TURkey,Australia, and china.my insighter connections have amdL australia in australia and jade in China partners of RAdient and UNi you understand.

"Our long term strategy and consideration for profit has given us a self-pay focus in Taiwan. However, we will respond to partner demand in countries like Turkey, Australia, and China when we bring Onko-Sure to those markets. We will reduce price, and give our distribution partners more space to be competitive and submit for reimbursement."

"FW: Our vision is to take this product to different countries. We think Onko-Sure can benefit patients throughout the entire world. We own the license to manufacture it in Taiwan, and to sell it in a number of global markets, mostly in Asia Pacific and the Middle East. Penetrating these markets—our first international foray with a product we manufacture ourselves—will be a huge step for us.

After we take that first step, we will look to develop an even better product."

jim...here is the plan.. Provista and arima connection ?

FW: We are also planning an IPO. As you can imagine, developing our own product internationally will be a very capital-intensive endeavor.

TL: We anticipate an IPO around 2016. We hope to raise about NT$300 million.

http://pharmaboardroom.com/interviews/interview-terry-lin-general-manager-and-freia-wei-senior-consultant-uni-pharma/

88888888888888888888888888***********************************************************************

This is All The DD and Rebuttals with ALL of the facts and findings you will ever need to know in ONE Quick Link and Page;

Why Radient Pharmaceuticals Public Shell will be utilized for The Proposed LOI of 2010 to reverse Merge with Provista Diagnostics.


Due Diligence: Analysis on Facts and Findings.


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113814338

JULY 14, 2015 and past posts

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=115395738